NON INVASIVE MONITORING SYSTEMS INC /FL/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NON INVASIVE MONITORING SYSTEMS INC /FL/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jul 31, 2017 | $6.0K | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | $23.0K | Oct 30, 2017 |
| FY2015 | Jul 31, 2015 | $0 | Oct 23, 2015 |
| FY2015 | Jul 31, 2014 | $13.0K | Oct 23, 2015 |
| FY2014 | Jul 31, 2013 | $109.0K | Oct 27, 2014 |
| FY2013 | Jul 31, 2012 | $250.0K | Oct 29, 2013 |
| FY2012 | Jul 31, 2011 | $743.0K | Oct 29, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($222.0K) | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | ($113.0K) | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | ($199.0K) | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | ($173.0K) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($158.0K) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | ($163.0K) | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | ($1.62M) | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | ($445.0K) | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | ($488.0K) | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | ($741.0K) | Oct 30, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($160.0K) | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | ($59.0K) | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | ($169.0K) | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | ($159.0K) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($158.0K) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | ($165.0K) | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | ($446.0K) | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | ($178.0K) | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | ($295.0K) | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | ($572.0K) | Oct 30, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jul 31, 2015 | $0 | Oct 23, 2015 |
| FY2015 | Jul 31, 2014 | $1.0K | Oct 23, 2015 |
| FY2014 | Jul 31, 2013 | $3.0K | Oct 27, 2014 |
| FY2013 | Jul 31, 2012 | $38.0K | Oct 29, 2013 |
| FY2012 | Jul 31, 2011 | $38.0K | Oct 29, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jul 31, 2019 | $446.0K | Nov 13, 2019 |
| FY2019 | Jul 31, 2018 | $178.0K | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | $201.0K | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | $259.0K | Oct 30, 2017 |
| FY2016 | Jul 31, 2015 | $255.0K | Oct 25, 2016 |
| FY2015 | Jul 31, 2014 | $319.0K | Oct 23, 2015 |
| FY2014 | Jul 31, 2013 | $444.0K | Oct 27, 2014 |
| FY2013 | Jul 31, 2012 | $599.0K | Oct 29, 2013 |
| FY2012 | Jul 31, 2011 | $1.37M | Oct 29, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($117.0K) | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | ($182.0K) | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | ($158.0K) | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | ($190.0K) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($148.0K) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | ($150.0K) | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | ($437.0K) | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | ($221.0K) | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | ($176.0K) | Nov 13, 2018 |
| FY2013 | Jul 31, 2013 | ($311.0K) | Oct 29, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $7.0K | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | $34.0K | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | $23.0K | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | $21.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $59.0K | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $206.0K | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | $361.0K | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $110.0K | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | $21.0K | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | $242.0K | Oct 30, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $954.0K | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | $759.0K | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | $635.0K | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | $434.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $299.0K | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $288.0K | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | $280.0K | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $3.79M | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | $3.25M | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | $2.99M | Oct 30, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($947.0K) | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | ($725.0K) | Jan 30, 2026 |
| FY2025 | Jul 31, 2023 | ($612.0K) | Jan 30, 2026 |
| FY2024 | Jul 31, 2022 | ($413.0K) | Oct 25, 2024 |
| FY2023 | Jul 31, 2021 | ($240.0K) | Oct 30, 2023 |
| FY2022 | Jul 31, 2020 | ($82.0K) | Oct 28, 2022 |
| FY2021 | Jul 31, 2019 | $81.0K | Oct 29, 2021 |
| FY2020 | Jul 31, 2018 | ($3.68M) | Oct 29, 2020 |
| FY2019 | Jul 31, 2017 | ($3.23M) | Nov 13, 2019 |
| FY2018 | Jul 31, 2016 | ($2.75M) | Nov 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($29.07M) | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | ($28.85M) | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | ($28.73M) | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | ($28.54M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($28.36M) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | ($28.20M) | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | ($28.04M) | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | ($26.46M) | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | ($26.02M) | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | ($25.53M) | Oct 30, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jul 31, 2023 | $7.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2022 | $15.0K | Oct 28, 2022 |
| FY2021 | Jul 31, 2021 | $55.0K | Oct 29, 2021 |
| FY2021 | Jul 31, 2020 | $203.0K | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | $353.0K | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $90.0K | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | $11.0K | Nov 13, 2018 |
| FY2018 | Jul 31, 2016 | $87.0K | Nov 13, 2018 |
| FY2017 | Jul 31, 2015 | $40.0K | Oct 30, 2017 |
| FY2016 | Jul 31, 2014 | $21.0K | Oct 25, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jul 31, 2017 | $1.93M | Oct 30, 2017 |
| FY2016 | Jul 31, 2016 | $1.73M | Oct 25, 2016 |
| FY2015 | Jul 31, 2015 | $1.40M | Oct 23, 2015 |
| FY2014 | Jul 31, 2014 | $1.20M | Oct 27, 2014 |
| FY2013 | Jul 31, 2013 | $1.20B | Oct 29, 2013 |
| FY2012 | Jul 31, 2012 | $1.15M | Oct 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | 0 | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | 0 | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | 0 | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 0 | Oct 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | 0 | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | 0 | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | 0 | Oct 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 154.81M | Jan 30, 2026 |
| FY2025 | Jul 31, 2024 | 154.81M | Jan 30, 2026 |
| FY2024 | Jul 31, 2023 | 154.81M | Oct 25, 2024 |
| FY2023 | Jul 31, 2022 | 154.81M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 154.81M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | 154.81M | Oct 29, 2021 |
| FY2020 | Jul 31, 2019 | 154.81M | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | 79.01M | Nov 13, 2019 |
| FY2018 | Jul 31, 2017 | 79.01M | Nov 13, 2018 |
| FY2017 | Jul 31, 2016 | 79.01M | Oct 30, 2017 |